OS Therapies Inc (New York Stock Exchange Arca:OSTX)
| Market Cap | $35.11M-60.9% |
| Revenue (ttm) | $0 |
| Net Income | -$39.37M-175.7% |
| EPS | -$1.09-87.9% |
| Shares Out | 46.81M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,334,388 |
| Open | $0.88 |
| Previous Close | $0.87 |
| Day's Range | $0.72 - $0.88 |
| 52-Week Range | $0.58 - $2.25 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About OSTX
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Next catalysts
- Nov 13, 2026Earnings report
$OSTX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in OSTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by OSTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
OSTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New OSTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to OSTX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in OSTX
| VTIVanguard Morningstar Total Stock Market ETF | $665.78K |
| VXFVanguard Extended Market ETF | $578.46K |
| IWCiShares Micro-Cap ETF | $93.88K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $40.00K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from OSTX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Strong clinical and regulatory momentum with statistically significant survival data and alignment from major regulatory bodies (FDA, MHRA, EMA) advancing OST-HER2 program.